Literature DB >> 18798715

Prospective observational study of levosimendan and weaning of difficult-to-wean ventilator dependent intensive care patients.

Martin Sterba1, Ashoke Banerjee, Yugan Mudaliar.   

Abstract

OBJECTIVE: To evaluate the role of levosimendan in improving cardiac performance and the success rate of weaning from mechanical ventilation in ventilatordependent, difficult-to-wean patients with impaired cardiac function in the intensive care unit. DESIGN AND
SETTING: Prospective, observational study in the ICU of Westmead Hospital, a university-affiliated tertiary referral hospital in Sydney, NSW, between January 2003 and October 2004. PATIENTS AND
INTERVENTIONS: 47 ICU patients who were ventilator-dependent for > or =10 days and had failed a weaning or extubation attempt due to respiratory insufficiency were identified as difficult to wean from mechanical ventilation. All were assessed by transthoracic or transoesophageal echocardiography. Twelve who had impaired left ventricular performance (demonstrated by left ventricular ejection fraction [LVEF] <40%) and were already established on diuretic and vasodilator treatment were given a 24-hour infusion of levosimendan. LVEF was measured again within 24 hours after infusion, and weaning from mechanical ventilation and extubation were re-attempted, when clinically deemed feasible.
RESULTS: Levosimendan administration was associated with significantly improved LVEF (28.3% before v 34.6% after, P=0.04) and PaO2/FIO2 ratio (179mmHg v 197mmHg, P=0.002) and reduced FIO2 (0.45 v 0.39, P=0.01). These changes were associated with significant improvement in the success rate in weaning from mechanical ventilation (P=0.02), with seven of the 12 patients successfully weaned after levosimendan therapy, and six surviving to hospital discharge. There was no significant difference in any other important parameter between pre- and post-levosimendan weaning attempts.
CONCLUSIONS: Levosimendan may provide significant benefit to ventilator-dependent patients with impaired left ventricular function. Randomised controlled trials appear justified.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18798715

Source DB:  PubMed          Journal:  Crit Care Resusc        ISSN: 1441-2772            Impact factor:   2.159


  8 in total

1.  Use of levosimendan in critically ill patients with severe aortic stenosis and left ventricular dysfunction.

Authors:  Francisca Caetano; Paula Mota; Sérgio Barra; Inês Almeida; Ana Botelho; Joana Trigo; António L Marques
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2012-12

Review 2.  Clinical review: the ABC of weaning failure--a structured approach.

Authors:  Leo M Heunks; Johannes G van der Hoeven
Journal:  Crit Care       Date:  2010-12-08       Impact factor: 9.097

3.  Temporary transvenous diaphragm pacing vs. standard of care for weaning from mechanical ventilation: study protocol for a randomized trial.

Authors:  Douglas Evans; Deborah Shure; Linda Clark; Gerard J Criner; Martin Dres; Marcelo Gama de Abreu; Franco Laghi; David McDonagh; Basil Petrof; Teresa Nelson; Thomas Similowski
Journal:  Trials       Date:  2019-01-17       Impact factor: 2.279

4.  Contribution of Levosimendan in Weaning from Mechanical Ventilation in Patients with Left Ventricular Dysfunction: A Pilot Study.

Authors:  Ifigeneia Kaltsi; Epameinondas Angelopoulos; Georgios Tzanis; Antonios Sideris; Konstantinos Tyrovolas; Stelios Kokkoris; Christina Gratziou; Serafeim Nanas; Christina Routsi
Journal:  Crit Care Res Pract       Date:  2019-07-24

Review 5.  Multiorgan Drug Action of Levosimendan in Critical Illnesses.

Authors:  Jian Pan; Yun-Mei Yang; Jian-Yong Zhu; Yuan-Qiang Lu
Journal:  Biomed Res Int       Date:  2019-09-19       Impact factor: 3.411

6.  Exercise Capacity Is Improved by Levosimendan in Heart Failure and Sarcopenia via Alleviation of Apoptosis of Skeletal Muscle.

Authors:  Di Wang; Ming Song; Long-Fei Shen; Lu Han; Ping Zhu; Xu Jia; Guo-Kai Shang; Yuan Cao; Wei Zhang; Ming Zhong; Zhi-Hao Wang
Journal:  Front Physiol       Date:  2022-01-20       Impact factor: 4.566

Review 7.  Levosimendan: current data, clinical use and future development.

Authors:  M S Nieminen; S Fruhwald; L M A Heunks; P K Suominen; A C Gordon; M Kivikko; P Pollesello
Journal:  Heart Lung Vessel       Date:  2013

Review 8.  Use of Levosimendan in Intensive Care Unit Settings: An Opinion Paper.

Authors:  Antoine Herpain; Stefaan Bouchez; Massimo Girardis; Fabio Guarracino; Johann Knotzer; Bruno Levy; Tobias Liebregts; Piero Pollesello; Sven-Erik Ricksten; Hynek Riha; Alain Rudiger; Fabio Sangalli
Journal:  J Cardiovasc Pharmacol       Date:  2019-01       Impact factor: 3.105

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.